L
Long H. Dang
Researcher at Ochsner Medical Center
Publications - 7
Citations - 222
Long H. Dang is an academic researcher from Ochsner Medical Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 4, co-authored 7 publications receiving 162 citations. Previous affiliations of Long H. Dang include Ochsner Health System & University of Michigan.
Papers
More filters
Journal ArticleDOI
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
Matthew D. Galsky,Amir Mortazavi,Matthew I. Milowsky,Saby George,Sumati Gupta,Mark D. Fleming,Long H. Dang,Daniel M. Geynisman,Radhika Walling,Robert S. Alter,Mohamad Kassar,Jue Wang,Shilpa Gupta,Nancy B. Davis,Joel Picus,George Philips,David I. Quinn,G. Kenneth Haines,Noah M. Hahn,Qianqian Zhao,Menggang Yu,Sumanta K. Pal +21 more
TL;DR: Switch maintenance pembrolizumab leads to additional objective responses in patients achieving at least stable disease with first-line platinum-based chemotherapy and prolongs progression-free survival in patients with metastatic urothelial cancer.
Journal ArticleDOI
Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition
Duyen T. Dang,Sang Y. Chun,Kyunghee Burkitt,Masako Abe,Shaowei Chen,Pamela A Havre,Nicola J. Mabjeesh,Elisabeth I. Heath,Nicholas J. Vogelzang,Marcia Cruz-Correa,Douglas W. Blayney,William D. Ensminger,Brad St. Croix,Nam H. Dang,Long H. Dang +14 more
TL;DR: The extent of tumor vessel response to angiogenic inhibition could be correlated with the preexisting coverage of tumor endothelial tubes with SMA+ pericytes and differential tumor induction of HIF-1 target genes.
Journal ArticleDOI
Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer.
Chintan Shah,Young-Rock Hong,Rohit Bishnoi,Azka Ali,William Paul Skelton,Long H. Dang,Jinhai Huo,Nam H. Dang +7 more
TL;DR: DPP4i seems to improve survival in PRC patients; however, not in PC or BC patients, and a prospective clinical trial would help to confirm these findings.
Journal ArticleDOI
Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.
Matthew D. Galsky,Sumanta K. Pal,Amir Mortazavi,Matthew I. Milowsky,Saby George,Sumati Gupta,Mark D. Fleming,Long H. Dang,Daniel M. Geynisman,Radhika Walling,Robert S. Alter,Erwin L. Robin,Jue Wang,Shilpa Gupta,David D. Chism,Joel Picus,George Philips,David I. Quinn,Noah M. Hahn,Menggang Yu +19 more
TL;DR: Platinum-based chemotherapy for 1st-line treatment of pts with metastatic urothelial cancer (mUC) is typically administered for a fixed duration followed by observation until recurr...
Journal ArticleDOI
A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer
William Paul Skelton,Samantha Welniak Dibenedetto,Sarah Pang,Kelsey Pan,Jacob Barish,Adaeze Nwosu-Iheme,Long H. Dang +6 more
TL;DR: A higher rate of Xofigo-induced pancytopenia is found in the patient population than the 2% reported in the literature, albeit with a limited sample size, which may influence clinical decision making in the treatment of mCRPC, as pancy topenia may preclude patients from other survival-prolonging therapies.